Stockhead’s Tylah Tully chats with  Botanix Pharmaceuticals (ASX:BOT) CEO Dr Howie McKibbon, to get the short end of the long story on the company’s latest news.

Botanix has recently been included in the ASX 300, which is part of the company’s focus to be the world’s largest and most innovative dermatology company.

Tune in as Howie discusses this new milestone and hear more about their next planned phase for the treatment of primary axillary hyperhydrosis.

This video was developed in collaboration with Botanix Pharmaceuticals, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Read MoreHealth

Featured Companies

You might be interested in